Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$6.0 - $9.37 $163,200 - $254,863
-27,200 Reduced 72.53%
10,300 $90,000
Q1 2022

May 11, 2022

SELL
$6.64 - $12.85 $172,640 - $334,100
-26,000 Reduced 40.94%
37,500 $300,000
Q2 2021

Aug 16, 2021

BUY
$10.43 - $12.81 $662,305 - $813,435
63,500 New
63,500 $738,000

Others Institutions Holding IMTX

About Immatics N.V.


  • Ticker IMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,227,000
  • Market Cap $623M
  • Description
  • Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...
More about IMTX
Track This Portfolio

Track Act Capital Management, LLC Portfolio

Follow Act Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Act Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Act Capital Management, LLC with notifications on news.